Molecular characterisation of RhD variants in North Indian blood donor population
- PMID: 32488899
- DOI: 10.1111/tme.12690
Molecular characterisation of RhD variants in North Indian blood donor population
Abstract
Objectives: A molecular analysis of serologically RhD variant samples was conducted to find the incidence of various D variants in our blood donor population.
Background: Determining a blood donor's RhD phenotype and genotype is important as transfusion of units with a weak D or partial D phenotype can result in immunisation of the recipients.
Methods: Samples with discrepant D and weak D phenotypes identified on testing with at least five different monoclonal anti-D antisera were considered serological RhD variant and subjected to molecular testing (Massarray kit, Agena Bioscience, San Diego) for variant RHD gene.
Results: A total of 39 samples, including 19 RhD discrepant samples and 20 weak D samples, were identified as serological RhD variant from a total of 4386 samples. Thirteen (13/39) samples carried variants leading to weak D phenotype, and eight samples had variants leading to partial D categories. Seven samples (7) could not be characterised, whereas 11 samples were identified as Rh negative (RHD*01N.01) after molecular testing. Overall incidence of D variants in the study population was 0.48%. RHD*weak D type 1(5, 0.1%) and RHD*DFR1 (5, 1%) were the most common variants identified.
Conclusions: Few samples with weak reaction on serological testing were found to be partial D variant and vice versa. Donor centres should develop a protocol for genotyping of samples with aberrant results on serological testing for assessing the actual RhD status of an individual as results of serological testing may be misleading.
Keywords: D variants; MALDI-TOF; RHD gene; RHD genotyping; mass array; prevalence; weak D.
© 2020 British Blood Transfusion Society.
References
REFERENCES
-
- Muller TH, Wagner FF, Trockenbacher A, et al. PCR screening for common weak D types shows different distributions in three central European populations. Transfusion. 2001;41:45-52.
-
- Daniels G. Variants of RhD-current testing and clinical consequences. Br J Haematol. 2013;161:461-470.
-
- Sandler SG, Flegel WA, Westhoff CM, et al. It's time to phase in RHD genotyping for patients with a serologic weak D phenotype. Transfusion. 2015;55:680-689.
-
- Carritt B, Kemp TJ, Poulter M. Evolution of the human RH (rhesus) blood group genes: a 50 year old prediction (partially) fulfilled. Hum Mol Genet. 1997;6:843-850.
-
- Wagner FF, Flegel WA. Review: the molecular basis of the Rh blood group phenotypes. Immunohematology. 2004;20:23-36.
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical